Market Overview

Goldman Sachs Swaps Perrigo, Johnson & Johnson Ratings

Share:
Goldman Sachs Swaps Perrigo, Johnson & Johnson Ratings
Related JNJ
Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares
Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4
The Passive DGI Core Portfolio: Midyear Review (Seeking Alpha)
Related PRGO
8 Biggest Price Target Changes For Thursday
Benzinga's Top Upgrades, Downgrades For July 12, 2018

The iShares Dow Jones US Healthcare (ETF) (NYSE: IYH) is up marginally year-to-date, but the profits aren’t bleeding into all health care constituents.

The Ratings

Goldman Sachs analyst Jami Rubin upgraded Johnson & Johnson (NYSE: JNJ) from Sell to Neutral and maintained a $134 price target. Rubin downgraded Perrigo Company PLC (NYSE: PRGO) from Neutral to Sell and cut the price target from $78 to $74.

The Thesis

Rubin had been bearish on Johnson & Johnson only for its valuation, which she considered unjustly high relative to peers and given its poor earnings growth. As the stock now trades comparably with the group, it’s earned an upgrade, the analyst said in a Thursday note. (See Rubin's track record here.) 

Goldman’s steady price target reflects pharma’s outperformance as well as durability in both consumer products and medical devices and diagnostics.

Perrigo’s downgrade is similarly justified by relative peer performance, Rubin said. 

“We see no meaningful risk to numbers but expect the business to drift due to a lack of meaningful new launches in the pipeline,” the analyst said, referencing developments by Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE: TEVA) and Mylan NV (NASDAQ: MYL).

Perrigo's stabilizing prescription business is not seen to lend meaningful upside.

“Now consumer [over-the-counter] drives 75 percent of PRGO’s operating profits, and this industry is facing headwinds that we do not expect to abate anytime soon." 

Price Action

Perrigo was trading down 1.94 percent at $76.25 at the time of publication, while Johnson & Johnson was up 1.05 percent at $127.56. 

Related Links:

Analyst: Despite Industry Woes, Investigations, And Management Shake-Up, Perrigo Is A Buy

Analyst: Morphosys Is Well-Positioned To Continue Success With Antibody Discovery Platforms

Latest Ratings for JNJ

DateFirmActionFromTo
Jul 2018Goldman SachsUpgradesSellNeutral
Jun 2018BernsteinInitiates Coverage OnMarket Perform
Apr 2018Credit SuisseMaintainsOutperformOutperform

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Upgrades Downgrades Health Care Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (IYH + JNJ)

View Comments and Join the Discussion!